137 related articles for article (PubMed ID: 20411818)
1. [Modulation of tissue exposure to cortisol, new perspective for reducing the metabolic risk associated with obesity].
Iovino A; Scheen AJ
Rev Med Liege; 2010 Mar; 65(3):140-6. PubMed ID: 20411818
[TBL] [Abstract][Full Text] [Related]
2. [Reduction of obesity-related metabolic risk by modulating tissue exposition to cortisol].
Iovino A; Paquot N; Scheen AJ
Rev Med Suisse; 2010 Sep; 6(260):1608-12. PubMed ID: 20853716
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 in obesity.
Wake DJ; Walker BR
Endocrine; 2006 Feb; 29(1):101-8. PubMed ID: 16622297
[TBL] [Abstract][Full Text] [Related]
4. 11β-Hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus.
Pereira CD; Azevedo I; Monteiro R; Martins MJ
Diabetes Obes Metab; 2012 Oct; 14(10):869-81. PubMed ID: 22321826
[TBL] [Abstract][Full Text] [Related]
5. Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11beta-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone.
Sandeep TC; Andrew R; Homer NZ; Andrews RC; Smith K; Walker BR
Diabetes; 2005 Mar; 54(3):872-9. PubMed ID: 15734867
[TBL] [Abstract][Full Text] [Related]
6. 11 beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
Wake DJ; Walker BR
Mol Cell Endocrinol; 2004 Feb; 215(1-2):45-54. PubMed ID: 15026174
[TBL] [Abstract][Full Text] [Related]
7. 11-Beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors in type 2 diabetes mellitus and obesity.
Hughes KA; Webster SP; Walker BR
Expert Opin Investig Drugs; 2008 Apr; 17(4):481-96. PubMed ID: 18363514
[TBL] [Abstract][Full Text] [Related]
8. Local and systemic impact of transcriptional up-regulation of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity.
Wake DJ; Rask E; Livingstone DE; Söderberg S; Olsson T; Walker BR
J Clin Endocrinol Metab; 2003 Aug; 88(8):3983-8. PubMed ID: 12915696
[TBL] [Abstract][Full Text] [Related]
9. Body fat distribution and cortisol metabolism in healthy men: enhanced 5beta-reductase and lower cortisol/cortisone metabolite ratios in men with fatty liver.
Westerbacka J; Yki-Järvinen H; Vehkavaara S; Häkkinen AM; Andrew R; Wake DJ; Seckl JR; Walker BR
J Clin Endocrinol Metab; 2003 Oct; 88(10):4924-31. PubMed ID: 14557475
[TBL] [Abstract][Full Text] [Related]
10. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?
Anagnostis P; Katsiki N; Adamidou F; Athyros VG; Karagiannis A; Kita M; Mikhailidis DP
Metabolism; 2013 Jan; 62(1):21-33. PubMed ID: 22652056
[TBL] [Abstract][Full Text] [Related]
11. [Importance of the 11β-hydroxysteroid dehydrogenase enzyme in clinical disorders].
Feldman K; Likó I; Nagy Z; Szappanos A; Grolmusz VK; Tóth M; Rácz K; Patócs A
Orv Hetil; 2013 Feb; 154(8):283-93. PubMed ID: 23419529
[TBL] [Abstract][Full Text] [Related]
12. Tissue production of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 and metabolic disease.
Walker BR; Andrew R
Ann N Y Acad Sci; 2006 Nov; 1083():165-84. PubMed ID: 17148739
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of 11β-hydroxysteroid dehydrogenase 1 by carbenoxolone affects glucose homeostasis and obesity in db/db mice.
Dhanesha N; Joharapurkar A; Shah G; Kshirsagar S; Dhote V; Sharma A; Jain M
Clin Exp Pharmacol Physiol; 2012 Jan; 39(1):69-77. PubMed ID: 22060140
[TBL] [Abstract][Full Text] [Related]
14. 11Beta-hydroxysteroid dehydrogenase type 1 in human disease: a novel therapeutic target.
Tomlinson JW
Minerva Endocrinol; 2005 Mar; 30(1):37-46. PubMed ID: 15877012
[TBL] [Abstract][Full Text] [Related]
15. The role and regulation of 11β-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
Stimson RH; Walker BR
Horm Mol Biol Clin Investig; 2013 Sep; 15(2):37-48. PubMed ID: 25436731
[TBL] [Abstract][Full Text] [Related]
16. Targeting the pre-receptor metabolism of cortisol as a novel therapy in obesity and diabetes.
Gathercole LL; Stewart PM
J Steroid Biochem Mol Biol; 2010 Oct; 122(1-3):21-7. PubMed ID: 20347978
[TBL] [Abstract][Full Text] [Related]
17. Obesity and corticosteroids: 11beta-hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease.
Morton NM
Mol Cell Endocrinol; 2010 Mar; 316(2):154-64. PubMed ID: 19804814
[TBL] [Abstract][Full Text] [Related]
18. Anti-diabetic and anti-adipogenic effects of a novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, 2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone (KR-66344).
Park JS; Rhee SD; Kang NS; Jung WH; Kim HY; Kim JH; Kang SK; Cheon HG; Ahn JH; Kim KY
Biochem Pharmacol; 2011 Apr; 81(8):1028-35. PubMed ID: 21315688
[TBL] [Abstract][Full Text] [Related]
19. [Tissue-specific changes in cortisol metabolism and their potential role in the metabolic syndrome].
Kerstens MN; Wolffenbuttel BH; Dullaart RP
Ned Tijdschr Geneeskd; 2005 Apr; 149(16):871-6. PubMed ID: 15868991
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of disease: Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a novel treatment for the metabolic syndrome.
Tomlinson JW; Stewart PM
Nat Clin Pract Endocrinol Metab; 2005 Dec; 1(2):92-9. PubMed ID: 16929377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
